# A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

> **NCT06364696** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Inc** · enrollment: 175 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** ASP4396

## Key facts

- **NCT ID:** NCT06364696
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364696, "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06364696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*